Author:
Lacouture M.E.,Reilly L.M.,Gerami P.,Guitart J.
Funder
Zell Scholarship from the Robert H Lurie Comprehensive Cancer Center
Reference47 articles.
1. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer;Grandinetti;Pharmacotherapy,2007
2. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5;Liu;Cancer Res,2006
3. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer;Faivre;J Clin Oncol,2006
4. Cutaneous side-effects of kinase inhibitors and blocking antibodies;Robert;Lancet Oncol,2005
5. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N Engl J Med,2007
Cited by
210 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献